NCT05551871 is a NA clinical trial of Simvastatin in Traumatic Brain Injury, sponsored by Assiut University.

Who is sponsoring NCT05551871?

NCT05551871 is sponsored by Assiut University.

What drugs are being tested in NCT05551871?

Interventions in NCT05551871: Simvastatin, Placebo drug.

What condition does NCT05551871 study?

NCT05551871 studies Traumatic Brain Injury.

Is NCT05551871 still recruiting?

NCT05551871 is currently status unknown. Last updated 10 October 2022.

Last reviewed 2022-10-10 · How we verify

NCT05551871

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Usage of Simvastatin in Mild to Moderate Traumatic Brain Injury (TBI) Patients. Could it Make a Difference?

Status unknown NA Last updated 10 October 2022

What this trial tests

NA trial testing Simvastatin in Traumatic Brain Injury in 60 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	1 October 2022
Primary completion	1 December 2023
Estimated completion	1 December 2023

Drugs / interventions tested

Simvastatin (simvastatin) — full drug profile →
Placebo drug — full drug profile →

Conditions studied

Traumatic Brain Injury — all drugs for Traumatic Brain Injury →

Sponsor

Assiut University

Who can join

Adults 18 to 60, any sex, with Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Traumatic brain injury (TBI) is a common cause of long-term neurological morbidity, with devastating personal and societal consequences. At present, no pharmacological intervention clearly improves outcomes, and therefore a compelling unmet clinical need remains. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or "statins," offer a potential novel therapeutic strategy for TBI. In this study the investigators will study primarily the effect of statins on 30-day mortality rate which is defined as death within 30 days of TBI presentation where the occurrence of TBI is hour 0 or day 0 and secondarily evaluation of duration of ICU stay associated with or without complications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of statins on neurological functional outcomes in critically ill adult patients with traumatic brain injury: a systematic review and meta-analysis.
Veillette C, Umana M, Gagnon MA, Costerousse O, et al · · 2025 · cited 1× · PMID 39971597 · DOI 10.1136/bmjopen-2024-091971

Verify or expand the search:

Other trials of Simvastatin

Trials testing the same drug.

NCT07102979 — Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbio · NA · enrolling by invitation
NCT06948747 — A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of E · Phase 1 · completed
NCT06858332 — Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia · recruiting
NCT07031778 — Topic Simvastatin for Bone Regeneration · EARLY_PHASE1 · recruiting
NCT06399783 — Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata · Phase 4 · not yet recruiting

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
NCT07455136 — A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Mon · recruiting
NCT07404761 — Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments · NA · recruiting
NCT07230002 — Effects of Moderate/Severe Traumatic Brain Injury in the Subacute or Chronic Phase on Locomotor Strategies Involved in N · NA · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05551871 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 10 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05551871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing